Acetanilide

Acetanilide

SCHEMBL3987435

CC(=O)Nc1ccccc1.[N]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.95
HSD17B10 Q99714 1/20 0.95
MAPT P10636 4/20 0.79
KMT2A Q03164 3/20 0.79
NPC1 O15118 2/20 0.79
RAB9A P51151 2/20 0.79
POLB P06746 2/20 0.79
TAAR1 Q96RJ0 1/20 0.79
GAA P10253 1/20 0.73
ALDH1A1 P00352 4/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
SMN1; SMN2 Q16637 3/20 0.64
CACNA1B Q00975 1/20 0.64
APBA1 Q02410 1/20 0.64
HTT P42858 1/20 0.62
TSHR P16473 3/20 0.61
EPHX1 P07099 2/20 0.61
TP53 P04637 1/20 0.61
EPHX2 P34913 1/20 0.61
CDK9 P50750 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetanilide SCHEMBL24681 0.97 NAPRT (1.00) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL16922180 0.97 NAPRT (1.00) NAPRTHSD17B10MAPTKMT2ANPC1
SCHEMBL19669626 0.97 NAPRT (1.00) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL3359084 0.97 NAPRT (1.00) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL1332076 0.97 NAPRT (1.00) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL11511638 0.95 NAPRT (0.95) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL11207565 0.95 NAPRT (0.95) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL5049604 0.95 NAPRT (0.95) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL5883922 0.95 NAPRT (0.95) NAPRTHSD17B10MAPTKMT2ANPC1
Acetanilide SCHEMBL9484601 0.95 NAPRT (0.95) NAPRTHSD17B10MAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed
US-4731451-A HERBICIDES MONSANTO COMPANY (US) 1988-03-15 US disclosed
US-4155744-A PREEMERGENCE MONSANTO COMPANY (US) 1979-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL NAPRT 303/4885HSD17B10 176/4885MAPT 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.